ロード中...

FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma

On August 16, 2018, the U.S. Food and Drug Administration approved lenvatinib (Lenvima, Eisai Inc.) for first‐line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on an international, multicenter, randomized, open‐label, noninferiority trial (REFLECT; NCT01...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Nair, Abhilasha, Reece, Kelie, Donoghue, Martha B., Yuan, Weishi (Vivian), Rodriguez, Lisa, Keegan, Patricia, Pazdur, Richard
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Inc. 2020
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930400/
https://ncbi.nlm.nih.gov/pubmed/33044793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13566
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!